Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SAN FRANCISCO, May 03, 2017 -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report first quarter financial results on Tuesday, May 9, 2017, after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
Audio Webcast
Interested parties may access a live audio webcast of the conference call via the investor section of the FibroGen website, www.fibrogen.com. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (888) 843-7419 (domestic) or (630) 652-3042 (international), and use passcode 44595888#.
Dial-In Information
Live (U.S./Canada): (888) 771-4371
Live (International): (847) 585-4405
Confirmation number: 44595888
About FibroGen
FibroGen, Inc., headquartered in San Francisco with subsidiary offices in Beijing and Shanghai, is a leading science-based biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat (FG-4592), the company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase 3 development for anemia in lower risk myelodysplastic syndromes (MDS). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit www.fibrogen.com.
Contact Karen L. Bergman Vice President, Investor Relations and Corporate Communications FibroGen, Inc. [email protected] (415) 978-1433
